Home > Oncology > ELCC 2022 > Advanced Non-Small Cell Lung Cancer > Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Furmonertinib outperforms gefitinib as first-line therapy in patients with EGFR-mutated NSCLC

Presented By
Dr Yuankai Shi, National Cancer Center, China
Presented by
Yuankai Shi National Cancer Center, China
Conference
ELCC 2022
Trial
Phase 3, FURLONG
Doi
https://doi.org/10.55788/6731aaae
In the phase 3 FURLONG study, the third-generation tyrosine kinase inhibitor furmonertinib significantly prolonged progression-free survival (PFS) in patients with treatment-naïve, EGFR-mutated, stage IIIB–IV non-small cell lung cancer (NSCLC), compared with gefitinib. Furmonertinib is an irreversible, selective, third-generation EGFR tyrosine kinase inhibitor. The phase 3, randomised, double-blind FURLONG study (NCT03787992) aimed to compare the efficacy and safety of furmonertinib versus gefitinib in untreated, advanced NSCLC patients with EGFR-sensitizing mutations. The trial enrolled 358 patients with treatment-naïve, stage IIIB–IV NSCLC whose tumours were EGFR mutation-positive. Patients were randomised 1:1 to receive furmonertinib 80 mg/day or gefitinib 250 mg/day first-line treatment. In the furmonertinib and gefitinib arms...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on